ePosters only

ePoster Submission

Submission deadline: Thursday, 20 September 2018

Please note that abstracts accepted as "ePosters only" will be displayed on terminals during the congress. However they will not be presented at a specific session. In addition all ePosters will be available on the ECTRIMS Online Library.

For your references please find below the ePoster numbers.

ePoster numbers

ePoster Number Abstract Title First name Last name
EP1291 Diagnostic value of enhancing lesions on post-contrast T1-weighted magnetic resonance images in patients with a clinically isolated syndrome María Díaz Sánchez
EP1292 The role of IgG index versus oligoclonal bands in patients with suspected multiple sclerosis Pål Berg-Hansen
EP1293 Clinically isolated syndrome: natural course and diagnostic criteria Mafalda Seabra
EP1294 Autonomic nervous system dysfunction in people with neuromyelitis optica spectrum disorders Luka Crnosija
EP1295 Russian cohort of patients with NMO and NMO spectrum disorders Taras Simaniv
EP1296 Establishing the diagnosis of multiple sclerosis in Croatian patients with clinically isolated syndrome: 2010 versus 2017 McDonald criteria Mario Habek
EP1298 Application of the Matthews's criteria to differentiate MS from NMOSD at disease onset in a Latin American cohort Edgar Carnero Contentti
EP1299 Brucellosis presenting as a longitudinally extensive transverse myelitis Bassem Yamout
EP1300 Experts' opinion on 2nd-line treatments failure criteria for patients with multiple sclerosis Jérôme De Sèze
EP1301 Recurrent myelitis with CLIPPERS imaging: a case report Kamilla D'Aveiro Fernandez
EP1302 Challenges in diagnosing OCB-negative MS - the importance of imaging Anne-Marie Landtblom
EP1303 Neurosarsoidosis: report of 30 cases. What about diagnosis dilemma? Clément Richard
EP1304 Safety of rituximab in NMOSD patients: a long time prospective observational study Vahid Shaygannejad
EP1305 The clinical spectrum of MOG antibody-associated demyelination: a retrospective case study Athanasios Papathanasiou
EP1306 Clinical characterization of patients suffering from both central and peripheral demyelinating autoimmune disorder Juliane Klehmet
EP1307 Clinical and imaging features of 14 patients with tumefactive multiple sclerosis Maria Victoria Castro Sanchez
EP1308 Tocilizumab after autologous hematopoietic stem cell transplantation in refractory neuromyelitis optica: a case report Chiara Rosa Mancinelli
EP1309 MS mimics; MRI-negative relapsing-remitting autoimmune encephalomyelitis, hidden in the psychogenic disorders population Daiki Takewaki
EP1310 Impact of cigarette and hookah smoking on NMOSD patients´ disability status Masoud Etemadifar
EP1311 Neuromyelitis optica spectrum disorder in third level hospitals of Ecuador Edgar Patricio Correa Díaz
EP1312 A longitudinal study of cognitive function in a Japanese cohort of NMO and MS Takahiro Wakasugi
EP1313 Early relapse after rituximab initiation in a patient with neuromyelitis optica spectrum disease and side effects to subsequent tozilizumab therapy: need for further treatment options? Ingrid Meinl
EP1314 Successful intravenous immunoglobulin treatment in a patient with relapsing MOG antibody-associated disease Elena Tsantes
EP1315 Familial multiple sclerosis Habtany Youness
EP1316 Baló's concentric sclerosis: study of clinico-radiological characteristics and therapeutic outcomes Ioannis Tzartos
EP1317 Clinical and demographic characteristics of relapsing-remitting multiple sclerosis in Kazakhstan Sairan Kozhakanova
EP1318 Retinal nerve fiber layer and ganglion cell inner plexiform layer in youth with serum myelin oligodendrocyte glycoprotein antibody positivity E. Ann Yeh
EP1319 Diagnostic value of oligoclonal bands in children: a Danish nationwide multicenter population-based cohort study Magnus Spangsberg Boesen
EP1320 Fatigue, depression and quality of life in children with multiple sclerosis: a French cohort study Kumaran Deiva
EP1321 Decreased thickness of peripapillar retinal nerve fiber layer may be present after years of the episode in some patients with pediatric acute disseminated encephalomyelitis Gemma Olivé-Cirera
EP1322 Differences in cerebrospinal fluid CXCL8, CXCL10, CXCL13 and MCP1 chemokines levels in paediatric clinically isolated syndrome and definitive multiple sclerosis Hana Nohejlova
EP1323 The challenges of predicting the future after the first inflammatory CNS event in pediatric patients Bruna Klein da Costa
EP1324 Pediatric acquired demyelination syndromes profile in a Brazilian center Renata Barbosa Paolilo
EP1326 The usefulness of evoked potentials in the initial diagnosis of multiple sclerosis in children Izabela Witek
EP1327 Clinical trials in pediatric multiple sclerosis : a British-French patient and parent perspective Justine Marie dit Calais
EP1328 Efficacy of therapy in pediatric MS during 2 years (single-site study) Maria Shumilina
EP1329 What changes with the 2017 McDonald criteria in CIS pediatric patients Bruna Klein da Costa
EP1331 Two pediatric cases of Anti-NMDA receptor encephalitis with MS-typical lesions Lydia Marcus
EP1332 Clinical observation and treatment approaches of child Devic opticomyelitits in Kazakh Aigerim Galym
EP1333 Cognitive and psychiatric problems as the first manifestation of multiple sclerosis in children Małgorzata Bilska
EP1334 Analysis of longitudinal free-living features from wearable biosensors in multiple sclerosis patients Cindy Gonzalez
EP1335 Unmet needs of patients transitioning to secondary progressive multiple sclerosis: qualitative findings for a resource development Alessandra Solari
EP1336 Predictors for conversion of radiologically isolated syndrome to multiple sclerosis Irem Çiftçi
EP1337 Upper extremity function and its relation with ambulatory impairment in multiple sclerosis Caspar E.P. van Munster
EP1338 Initial MRI lesion load: a predictor of long-term disability independent of suggestive event Antoine Gueguen
EP1339 Exploring the outcome of multiple sclerosis (MS) among Saudi adult patients: a single-centered cross-sectional study at King Abdulaziz Medical City (KAMC) Ahmad Abulaban
EP1340 Mental health status among children of mothers diagnosed with multiple sclerosis: a Danish cohort and register-based study Johanna Balslev Andersen
EP1341 Burden of multiple sclerosis in Eastern Mediterranean Region: findings from the 2016 Global Burden of Disease study Mohammad Ali A. Sahraian
EP1342 Treatment patterns of multiple sclerosis patients treated with disease-modifying therapies in Puerto Rico Lobat Hashemi
EP1343 Temporal trends on the incidence of multiple sclerosis in Santiago de Compostela (Spain) Eva Costa Arpín
EP1344 Validity and reliability of multiple sclerosis minimum data set form for national registry system in Iran Sharareh Eskandarieh
EP1345 Clinical characteristics and personality traits influence how people with MS look for medical information Virginia Meca-Lallana
EP1346 Mastery is significantly associated with greater physical and mental health-related quality of life in two independently recruited international samples of people with multiple sclerosis Steve Simpson, Jr.
EP1347 Use of mobile health technology in establishment of multiple sclerosis (MS) registry in Iran: a study of stakeholders' attitude Omid Beiki
EP1348 Epidemiology of multiple sclerosis in Ardabil, northwest of Iran Negar Molazadeh
EP1349 Clinico-demographic characterization of a large cohort of neurological patients referred to the neuro-immunology outpatient clinic of Columbia University Medical Center Claire Riley
EP1350 Does socio-economic status influence early diagnosis and access to MS services? Holly Lyle
EP1351 High prevalence area of ​​multiple sclerosis in the far west of Algeria Zahira Barka bedrane
EP1352 The impact of stigma in people with primary progressive multiple sclerosis Francesc Pérez-Miralles
EP1353 Epidemiology of multiple sclerosis in the Highlands of Scotland: prevalence, incidence and mortality Francisco Javier Carod-Artal
EP1354 Time to get proper diagnosis in multiple sclerosis and start disease-modifying therapy: the Highlands MS incidence study Francisco Javier Carod-Artal
EP1355 Prevalence of multiple sclerosis in Cuenca, Ecuador Edgar Patricio Correa Díaz
EP1356 Pattern of demyelinating disorders in a tertiary medical center in India Anup Thacker
EP1357 Early versus late start of vitamin D supplementation in multiple sclerosis predicts short term disease course: a two-year observational study Paolo Ragonese
EP1358 A descriptive study of switching patterns among MS patients who started on Glatopa therapy: a claims database analysis Jessica Alexander
EP1359 The OFSEP high definition cohort: to prognosticate the evolution of multiple sclerosis at clinical key steps of the disease Romain Casey
EP1360 Use of anxiety and depression treatment in Hispanic multiple sclerosis patients of San Juan MS Center Astrid Diaz
EP1361 Characteristics of multiple sclerosis patients treated with disease-modifying therapies in Puerto Rico Lobat Hashemi
EP1362 Female to male ratio trend of multiple sclerosis in Tehran, Iran Sharareh Eskandarieh
EP1363 The role of heavy metals in genesis of multiple sclerosis in the population of various districts of Tashkent city Gulshanbonu Suyunova
EP1364 The study of the gender value of the degree of asthenic syndrome according to the test "SAM" in patients with multiple sclerosis Yulduz Parpiyeva
EP1365 Exclusive breastfeeding does not affect postpartum exacerbations Maria Shumilina
EP1366 Rebound in disease activity after fingolimod suspension for pregnancy planning: predictor factors Maria Sepulveda
EP1367 Cesarean section in women with MS: a choice or a need? Laura De Giglio
EP1368 The presence of MR-activity before and after pregnancy is associated with the probability of postpartum exacerbations Maria Shumilina
EP1369 Effects of sex-related factors on probability of disability in women with multiple sclerosis Ilknur Hosgel
EP1370 Pregnancy outcomes in Chilean MS patients receiving interferon beta or glatiramer acetate: a longitudinal 8 year study Bernardita Soler
EP1371 Workplace difficulties, health-related quality of life and perception of stigma in people with multiple sclerosis with low physical disability José M García-Domínguez
EP1372 Autonomic nervous system dysfunction is an independent contributor to multiple sclerosis related fatigue Luka Crnosija
EP1373 Persons with MS are at increased risk of osteopenia and osteoporosis. A ten-year longitudinal study Margitta T Kampman
EP1374 Sexual dysfunction in patients with multiple sclerosis: association with disability, anxiety, depression and fatigue Edgar Carnero Contentti
EP1375 Quality of life and SR-fampridine in multiple sclerosis patients Nathalie Derache
EP1376 Evolution of afferent trigeminal system involvement in patients with clinically isolated syndrome over two-year follow-up Tereza Gabelic
EP1377 Association between cognitive functions, balance, and walking in persons with multiple sclerosis with minimal disability Hatice Ayan
EP1378 Risk factors associated with falls in persons with multiple sclerosis: an observational study Zuhal Abasiyanik
EP1380 Physician- and patient-derived sources of error estimating prevalence of pseudobulbar affect in an academic multiple sclerosis referral center John R. Rinker
EP1381 Reverse takotsubo cardiomyopathy in the setting of active multiple sclerosis lesion involving the medulla oblongata Frédéric London
EP1382 Management of multiple sclerosis - related trigeminal neuralgia in Italian centres Diana Ferraro
EP1383 Cognitive function as measured by SDMT is associated with employment status in an Australian MS cohort​ Jeannette Lechner-Scott
EP1384 Factors related to restless leg syndrome in multiple sclerosis Asiye Tuba Ozdogar
EP1385 Fatigue and related factors in persons with multiple sclerosis Cavid Babayev
EP1386 Speech profile of multiple sclerosis patients admitted to a neurorehabilitation unit María Laura Saladino
EP1387 Benign multiple sclerosis patients display increased prevalence of sleep disorders Recai Türkoğlu
EP1388 Tracking symptom impact in MS patients: longitudinal study of symptoMScreen scores in patients attending two large tertiary MS centers Ilya Kister
EP1389 The effect of spasticity on the walking speed and quality of life in patients with multiple sclerosis Judit Füvesi
EP1390 Predictors of long term disability progression in patients with relapsing remitting multiple sclerosis Valentina Ignatova
EP1391 The effect of the decrease in walking distance and speed on the quality of life and activities of daily living in patients with multiple sclerosis Judit Füvesi
EP1392 Sleep disorders sub-estimated during multiple sclerosis - study of a series of Algerian patients Barka Bedrane zahira
EP1393 Translation in "Arab" and "Moroccan dialect" adaptation and validation of the modified fatigue impact scale during multiple sclerosis Habtany Youness
EP1394 Short-term effects of inpatient multidisciplinary rehabilitation in multiple sclerosis: clinical predictors from a large-scale, single-center study Elisabetta Groppo
EP1395 Treatment burden in multiple sclerosis Maria Celica Ysrraelit
EP1396 SCOPOUSEP: a predictive model for scoring the severity of relapses in multiple sclerosis Laure Michel
EP1397 Validation study of the MS-COG-e scale at 60 seconds cut-off point. A new electronic and brief neuropsychological scale to detect cognitive impairment (CI) in patients with multiple sclerosis (MS) Jose Eustasio Meca Lallana
EP1398 Longitudinal assessment of upper limb function by an engineered glove reveals a deterioration not captured by the EDSS over 7 years in patients with multiple sclerosis Caterina Lapucci
EP1399 Social functioning with regard to impact of the disease in the patients with multiple sclerosis Anna Pokryszko-Dragan
EP1400 Validity and potential added value of multi-domain computerized cognitive assessment for patients with multiple sclerosis Daniel Golan
EP1401 Factors associated with falls in multiple sclerosis Raminta Macaitytė
EP1402 Upper limb function in MS: correlation between instrumental and clinical scale Claudio Solaro
EP1403 Pilot Study of Telemedicine in multiple sclerosis to evaluate the effectiveness of a telecommunication system for the detection of the clinical activity of the disease in the number of relapses with respect to the standard clinical practice. TELEM Anna Gil
EP1404 Coping in multiple sclerosis: qualitative analysis of themes Carolyn A. Young
EP1405 Fatigue, patient reported outcomes, and sleep apnea in people with multiple sclerosis: perception is insufficient to just sleep on it Jared Srinivasan
EP1406 Multiple sclerosis and EDSS: a closer inspection of the Walking Scale finds erratic walking Jared Srinivasan
EP1407 Assessment of cognitive function in early stages of multiple sclerosis. Validation of BICAMS in Norway Ellen Skorve
EP1408 A preliminary investigation into the relationship between the Multiple Sclerosis Walking Scale (MSWS-12) and an objective multi-dimensional digital gait analysis Mark Gudesblatt
EP1409 Making precision medicine work at the bedside without a universal health record: the MS BioScreen experience Riley Bove
EP1410 Validation of the Spanish version of the Treatment Burden Questionnaire in multiple sclerosis patients Marcela Paula Fiol
EP1411 Reliability and validity of the activities-specific Balance Confidence scale and Fall Efficacy Scale-International in Iranian patients with multiple sclerosis Saeideh Monjezi
EP1412 Evaluation of changes in cognitive function as assessed by NeuroTrax in patients with multiple sclerosis treated with natalizumab for up to 5 years Mark Gudesblatt
EP1413 Rapid foot-tapping but not hand-tapping ability distinguishes between multiple sclerosis subtypes Sumire Sato
EP1414 Evolution of dysautonomia in patients with clinically isolated syndrome over two-year follow-up Ivan Adamec
EP1415 Do you exercise regularly? Psychometric analysis of a single question for assessing physical activity in people with multiple sclerosis Turhan Kahraman
EP1416 Value of the MoCA test to detect cognitive impairment in MS patients without subjective cognitive complaints Isabelle Rouleau
EP1417 Timely intervention, monitoring and education MATTERS in multiple sclerosis (TIME MATTERS in MS): developing a globally applicable quality improvement tool Jeremy Hobart
EP1418 Upper limb function in MS: creation of a normative data set on subjective and objective measures and the construction of an MS-specific assessment tool Claudio Solaro
EP1419 Hope in multiple sclerosis: qualitative analysis of concepts and domains Carolyn A. Young
EP1420 Multi-domain analysis of cognitive impairment in people with multiple sclerosis (PwMS): relationship of the number of cognitive domains impaired ( Mark Gudesblatt
EP1421 Investigation into the relationship between digital brain volume and computerized screening assessment of cognitive function in people with multiple sclerosis: objective analytics to quantify disease impact Mark Gudesblatt
EP1422 Investigation into the relationship between patient reported disease severity (MSIS-29) and a multi-domain objective computerized screening cognitive analysis aattery in people with multiple sclerosis Mark Gudesblatt
EP1424 Reliability, validity and responsiveness of the timed 360⁰ turn test in multiple sclerosis Fatih Söke
EP1425 A new test for the measuring balance in multiple sclerosis: psychometric evaluation of the Static Balance Test Fatih Söke
EP1426 MMP-9 activity dynamics in relapsing-remitting multiple sclerosis patients under natalizumab treatment and their relationship to JCV reactivation and T-lymphocyte phenotypes Maria Antonella Zingaropoli
EP1427 Relationship between upper and lower limb impairments objectively assessed in people with multiple sclerosis Giancarlo Coghe
EP1428 Quality of life and some features of social functioning in multiple sclerosis Gulshanbonu Suyunova
EP1429 Impact of multiple sclerosis on the occupational status in developing countries. An experience in Argentina Judith Steinberg
EP1430 The value of multiple sclerosis caregiver burden scale. An Argentinean population Judith Steinberg
EP1431 Development of the adaptive, bilingual multiple sclerosis Health Resource Survey (MS-HRS) Rocco Haase
EP1432 Work related and quality of life consequences of early multiple sclerosis Jorge Correale
EP1433 Impact of socioeconomic level on the employment status of people with multiple sclerosis Natalia Ciufia
EP1434 Decreasing emergency department utilization in a multiple sclerosis patient-centered specialty practice: an advanced multimodal approach Susan Stuart
EP1435 Reduced sick leave in multiple sclerosis after switch from first-line disease-modifying drugs (interferon beta or glatirameracetat) to fingolimod Anne Wickström
EP1436 Driving continuous improvement of MS care quality - initial launch experience from the first continuous quality improvement research learning health system in multiple sclerosis-The Multiple Sclerosis Continuous Quality Improvement (MS-CQI) Brant Oliver
EP1437 Burden of multiple sclerosis in Brazil Gisela Kobelt
EP1438 Employment status in patients with multiple sclerosis: a cross-sectional study in Argentina Edgar Carnero Contentti
EP1439 New oral treatments decrease the switch to second-line therapies in multiple sclerosis. A 9-years retrospective, clinical and budget impact study Augustin Oterino Duran
EP1440 The neuro-opthalmological evaluation of multiple sclerosis' and neuromyelitis optica's optic neuritis: analysis of 238 cases Fethi Idiman
EP1441 Evaluation of pupillary response characteristics measured by pupillometry in differentiating MS from NMOSD with the machine-learning approach: a potential pupillary pattern recognition method Sara Samadzadeh
EP1442 Characteristics of optic neuropathy in Behcet´s disease Gulsen Akman-Demir
EP1443 Developmental venous anomalies are more common in patients with multiple sclerosis & clinically isolated syndrome: co-incidence or clinically relevant? Patrick Kruczek
EP1444 Comorbidities and safety of use of MD1003 in a cohort of patients with progressive multiple sclerosis Cecile Donze
EP1445 Prevalence of cancer and the relationship to disease-modifying treatments in a cohort of multiple sclerosis patients over 50 years of age Irene Moreno Torres
EP1446 Double jeopardy of multiple sclerosis and idiopathic Parkinson's disease: three new case reports Alexander Scarborough
EP1447 The relationship between migraine and multiple sclerosis therapies Yesim Beckmann
EP1448 Pain in AQP4-ab-positive and MOG-ab-positive neuromyelitis optica spectrum disorders Susanna Asseyer
EP1449 Multiple sclerosis related headaches. Prevalence and classification Hatem Shehata
EP1450 Multiple sclerosis clinical trials: how to encourage patients participation? Results from an observational study conducted via Carenity, a worldwide online patient community Roman Dos Santos
EP1451 Monocyte-derived tissue transglutaminase in multiple sclerosis patients: reflecting an anti-inflammatory status of the cells? Anne-Marie van Dam
EP1452 RGC-32 regulates TGF-β-induced reactive astrogliosis in a mouse model of multiple sclerosis Alexandru Tatomir
EP1453 IL-18 improves the activation of encephalytogenic cells and the induction of adoptively transferred experimental autoimmune encephalomyelitis Ruth García Hernández
EP1454 Comparative study of reverse transcriptase polymerase chain reaction and fluorescence-activated cell sorting for quantitating B cells after anti-CD20 monoclonal antibody therapy Gisbert Weckbecker
EP1455 A2AR antagonism in acute EAE model leads to early and more severe EAE Marjo Nylund
EP1457 Oleanolic acid protects against gastrointestinal disturbances in the experimental autoimmune encephalomyelitis model of multiple sclerosis Beatriz Gutierrez
EP1458 Impact of A20 deficiency in myeloid cells: study in a murine model Serena Martire
EP1459 Expression of the Nerve Growth Factor and its receptors, TrkA and p75NTR, in the spinal cord in Experimental Autoimmune Encephalomyelitis Nikolaos Grigoriadis
EP1460 Difference of tissue-specific networks where the associated genes are densely interconnected between Japanese and European descent patients with MS Takuya Matsushita
EP1461 Cross-sectional and longitudinal analysis of clinical parameters in a large-scale, national, multicentric multiple sclerosis cohort and the influence of MC1R SNPs Patrick Ostkamp
EP1462 Involvement of NINJ2 in inflammatory activity in MS Silvia Peroni
EP1463 A whole-exome sequencing approach in multiplex Italian multiple sclerosis families to identify new genes involved in the disease Elisabetta Mascia
EP1465 Functional relevance for CXCR5 variants associated with multiple sclerosis Elia Gil-Varea
EP1466 The MS risk variant rs2762943 of the CYP24A1 gene is associated with decreased serum levels of the active form of vitamin D Elia Gil-Varea
EP1467 Long noncoding RNA-Ccr2-5As and THRIL as novel prognostic epigenetic biomarkers in patients with multiple sclerosis Amr Hassan
EP1468 Multiple sclerosis genetic risk variants correlate with protein expression in monocytes of relapsing remitting patients: a protein quantitative trait loci study Laura Ferrè
EP1469 Genome-wide DNA methylation in secondary progressive multiple sclerosis patients reveals unique epigenetic signature Kira Groen
EP1470 Circulating miR-320b and miR-421 are deregulated in primary progressive MS patients María Muñoz-San Martín
EP1471 Total absence of the dominant HLA-DRB1*15 allele among patients with positive and most frequent HLA-DPB1*03, in a Hellenic cohort with multiple sclerosis Maria Anagnostouli
EP1472 Family distribution in multiple sclerosis: a study of the prevalence of familial recurrence in Puerto Rico Cristina Rubi
EP1473 A possible association between circulating vitamin D and haptoglobin concentrations in multiple sclerosis patients Zhila Maghbooli
EP1474 360° immune-profiling reveals new pathogenic immune cell subsets in multiple sclerosis: effects of glatiramer acetate Luca Battistini
EP1475 The difference of intercellular cytokine profiles among MOG+CNS disorders, AQP4+NMOSD, and MS patients Jia Liu
EP1476 Neuromyelitis optica and the role of Foxp3+ regulatory T cells Livnat Brill
EP1477 Characterization of the immunophenotye of clinically isolated syndrome patients and conversion to multiple sclerosis Chieh-Hsin Lee
EP1478 The contribution of monocytes and the purinergic receptor, P2X7, in MS relapse Mastura Monif
EP1479 T cell receptor repertoire in multiple sclerosis patients Fumie Hayashi
EP1480 CSF kappa light chain ratios potential prognostic impact in clinically isolated syndrome conversion to multiple sclerosis Manuel Salavisa
EP1481 In vitro verification of in silico predicted antigenic properties of intrathecal B cell receptor repertoires - a pilot study Rune A. Høglund
EP1482 Could basal levels of B cells and memory B cells identify responders to disease modifying treatments for MS? Ester Quintana
EP1483 Vitamin D levels and epidemiology of multiple sclerosis in Spain: Madrid vs Lanzarote Silvia Perez Perez
EP1484 Serum levels of leptin and adiponectin are not associated with disease activity or treatment response in multiple sclerosis Silje Stokke Kvistad
EP1485 Ditary animal protein sources in relation to risk of neuromyelitis optica spectrum disorder Nasim Rezaeimanesh
EP1486 Environmental risk factors for NMO-IgG sero-positivity in neuromyelitis optica spectrum disorder Sharareh Eskandarieh
EP1487 Vitamin D and body mass index in Egyptian multiple sclerosis patients Dina zamzam
EP1488 Coffee intake and multiple sclerosis disability Sara Duarte
EP1489 High dietary carbohydrate to protein ratio as a risk factor for neuromyelitis optica spectrum disorder: a case-control study Soodeh Razeghi Jahromi
EP1490 Incidence of multiple sclerosis following bariatric surgery: a case series Foziah Alshamrani
EP1491 Diet during adolescence and its association with multiple sclerosis in Bogota, Colombia Jorge Patiño
EP1492 Interoception as a neurocognitive mechanism underlying fatigue in multiple sclerosis Fatima Pagani Cassara
EP1493 The phosphatase CPI-17 as a regulator of oligodendrocyte degeneration Newshan Behrangi
EP1494 Different blood-brain barrier disruption profile in multiple sclerosis, neuromyelitis optica spectrum disorders and neuropsychiatric systemic lupus erythematosus Alicja Kalinowska-Lyszczarz
EP1495 NR4A impairment in multiple sclerosis patients: defects in blood and in central nervous system Francesca Montarolo
EP1496 Intrathecal syntheis of free light chains of immunoglobulins is associated with brain atrophy in multiple sclerosis Vladimir Nazarov
EP1497 Brain atrophy in multiple sclerosis: how patients understand the role of brain atrophy in the management of their MS Amanda Montague
EP1498 Corneal confocal microscopy detects progressive axonal degeneration in patients with multiple sclerosis which is progressive Ioannis Nikolaos Petropoulos
EP1499 Investigation of astrocytic functions and involvement in remyelination in an animal model of multiple sclerosis Sonja Hochmeister
EP1500 Reduced levels of Coco in the sera of patients with RRMS may be related to the insufficient oligodendrogenesis and neurogenesis Karin Mausner-Fainberg
EP1501 AZD4547, a potent FGFR inhibitor, regulates myelin gene expression in OLN-93 oligodendrocytes Bischand Sharifi
EP1502 Myelin related gene expression in oligodendrocytes is regulated by FGFR inhibition with BGJ398 in vitro Vinothkumar Rajendran
EP1503 Brain and deep grey-matter atrophy in relapsing-remitting multiple sclerosis with cortical lesions based on double inversion recovery MRI M. Andrea Parra
EP1504 Gray and white matter brain pathology in highly active multiple sclerosis patients Francisco Sanchez
EP1505 Multi-modal MRI intensity distributions reveal differences in normal-appearing white matter between MS subtypes Jordan Dworkin
EP1506 Radiological characteristics of patients with multiple sclerosis in Egypt Mohamed abdelHafeez
EP1507 Cognitive phenotypes in MS: underlying changes in structural connectivity Elisabeth Solana
EP1508 High reproducibility and robustness to lesions, but large software and scanner effects for mean upper cervical cord area (MUCCA) measurement in MS Hugo Vrenken
EP1509 A magnetoencephalographic investigation of working memory function in MS Lars Costers
EP1510 Identifying pathological brain volume loss in individual early MS patients Roland Opfer
EP1511 Rapid reduction of lesion accumulation in specific white matter tracts as assessed by lesion mapping in relapsing-remitting MS patients treated with IFN beta-1a Antonio Giorgio
EP1512 Quantification of lesion evolution in primary progressive and relapsing remitting MS Wim Van Hecke
EP1513 Comparison of 24 month changes in brain volume among long term users of fingolimod versus glatiramer acetate in patients with multiple sclerosis Justin Morris Honce
EP1514 Microstructural changes in the mesocorticolimbic fiber pathway may play a role in the comorbid development of fatigue and depression in multiple sclerosis Miklos Palotai
EP1515 Structural MRI correlates of PASAT performance in multiple sclerosis Vanesa Pytel
EP1516 Longitudinal changes in advanced diffusion MRI of normal-appearing white matter and chronic lesions in ocrelizumab treated relapsing MS Anika Wurl
EP1517 Surface-based cortical gray matter correlates of personality traits in multiple sclerosis Tom Fuchs
EP1518 The impact of field strength on structural network organization: a comparative study between 3T and 7T in multiple sclerosis patients Muthuraman Muthuraman
EP1519 Resting-state functional correlates of social cognition in multiple sclerosis Renato Docimo
EP1520 Training a pattern classifier to distinguish cognitive phenotypes in multiple sclerosis Korhan Buyukturkoglu
EP1521 Signal mass change as a marker of brain tissue loss in multiple sclerosis patients following immunoablative therapy and autologous hematopoietic stem cell transplantation Hyunwoo Lee
EP1522 A deep learning based semantic segmentation framework for multiple sclerosis in MRI Sidong Liu
EP1523 Brain atrophy correction in longitudinal neuroimaging analysis of chronic white matter lesions Sidong Liu
EP1524 Relationship between cortical grey matter volume and cognitive impairment perception in multiple sclerosis Giuseppe Fenu
EP1525 Decreased interhemispheric connectivity in multiple sclerosis Johan Baijot
EP1526 A distributed platform for making large scale manual reference datasets for MS lesion segmentation Soheil Damangir
EP1527 Identification of cortical and subcortical correlates of cognitive performance in multiple sclerosis using voxel-based morphometry Vanesa Pytel
EP1528 Correlation between retinal Optical Coherence Tomography Measures and cognitive/physical disability in patients with early multiple sclerosis: a prospective study Hala Darwish
EP1529 The role of optical coherence tomography as a predictor of cognitive impairment in multiple sclerosis Cláudia Lima
EP1530 Cross-sectional OCT study of ON and non-ON MS eyes: non-effect of smoking exposure Mattia Rosso
EP1531 Expanding access to cognitive screening for individuals with multiple sclerosis: preliminary examination of two free web-based processing speed tests compared to the Symbol Digit Modalities Test Jagriti Bhattarai
EP1532 Functional MRI correlations between fatigue and cognitive performance in patients with relapsing remitting MS Dessislava Iancheva
EP1533 The impact of psychological resilience on cognitive and physical measures of disability in multiple sclerosis Sylvia Klineova
EP1534 Cognitive impairment in multiple sclerosis is reflected by increased susceptibility for sound-induced flash illusion Yavor Yalachkov
EP1535 Cognitive-motor interference while walking in people with multiple sclerosis: a potential maker of functional impairment? Barbara Postigo-Alonso
EP1536 The relationship between incidental learning and executive functions in relapsing remitting multiple sclerosis patients Vladimiro Sinay
EP1537 Decision making under explicit risk and prefrontal and thalamus volumes in multiple sclerosis patients Yolanda Aladro Benito
EP1538 Abnormal network connectivity related to social cognition in relapsing remitting multiple sclerosis Tomas Labbe
EP1539 Baseline cognitive function of patients with relapsing remitting multiple sclerosis is associated with therapeutic response to natalizumab Daniel Golan
EP1540 Social cognition deficits in early multiple sclerosis Jorge Correale
EP1541 Impaired natural viewing behaviour reflects cognitive impairment in multiple sclerosis- an eye-tracking study Johannes Gehrig
EP1542 Neuropsychological correlates of fatigue in multiple sclerosis Moussa A. Chalah
EP1543 Study of the relationship between executive functioning and episodic memory performance in multiple sclerosis using the Test of Memory Strategies Fabiola Garcia-Vaz
EP1544 The 15-15 PASAT 3” approach to study congnitive fatigue in multiple sclerosis Yolanda Higueras
EP1545 A systematic literature review: the relation between cognitive functioning and work outcomes in patients with multiple sclerosis Dennis Adrianus Martinus van Gorp
EP1546 Performance on a digital neuropsychological test battery in individuals with relapsing remitting multiple sclerosis and healthy controls. Normative values Vladimiro Sinay
EP1547 Correlation of fatigue with cognitive and emotional variables in a Portuguese group of multiple sclerosis patients Telma Miranda
EP1548 Dynamics of cognitive dysfunction profile in patients with multiple sclerosis based on their disease duration Todor Kunchev
EP1549 Cognitive performance of RRMS patients at the time of diagnosis: one step before the concept of cognitive impairment Maddalena Guandalini
EP1551 Validation of the Brief International Cognitive Assessment for multiple sclerosis (BICAMS) in a Colombian population Andrea Nicole Alarcón
EP1552 Spanish adaptation of the multiple sclerosis and vocational accommodations in multiple sclerosis patients Sandra Vanotti
EP1553 Alternative splicing in multiple sclerosis: a systematic review of the literature and validation in transcriptome data Michael Hecker
EP1554 Expression levels of apoptosis-related molecules in peripheral blood cells of multiple sclerosis patients Sunny Malhotra
EP1555 Serum levels of mir-128-3p are associated to clinical course and disease activity in multiple sclerosis Mattia Zanoni
EP1556 Biomarker discovery in tears of multiple sclerosis patients: a new vision in medicine? Marianne Dor
EP1557 Plasma neurofilaments correlate with disability in progressive multiple sclerosis patients Diana Ferraro
EP1558 Collection of tear fluid from multiple sclerosis patients for the investigation of oligoclonal IgG bands Franziska Bachhuber
EP1559 Elevation of Chi3l1 in acute disseminated encephalomyelitis: implications in pathogenesis Sara Gil-Perotin
EP1560 Longitudinal expression of gluco- and mineralocorticoid receptors and their targets in multiple sclerosis Clemens Goedel
EP1561 Sonographic optic nerve sheath diameter versus optic coherence tomography as a biomarker for disability in patients with multiple sclerosis Amr Hassan
EP1562 Searching for early CSF biomarkers of primary progressive multiple sclerosis Damiano Marastoni
EP1563 The expression in PBMCs of a subset of microRNA is able to differentiate MS patients with lipid-specific oligoclonal IgM bands Maider Muñoz-Culla
EP1564 Comparable sNFL levels in a NEDA-3 cohort of RRMS patients irrespective of different immunomodulatory therapies Johannes Piepgras
EP1565 Characterizing cytokine changes before and after ocrelizumab infusions and their contribution to infusion related reactions Ian Shelton
EP1566 CSF biomarkers of neurodegeration in early multiple sclerosis course Domizia Vecchio
EP1567 Serum neurofilament light chain in MS: association with clinical and MRI measures Emanuela Oldoni
EP1568 Hemostasis biomarkers in multiple sclerosis Bakhtigul Kholmuratova
EP1569 Blood-brain barrier-activation induced by immunoglobulin G in multiple sclerosis Fumitaka Shimizu
EP1570 gMS-classifier1 does not predict disability progression in multiple sclerosis Johannis Adam van Rossum
EP1571 Characterization of serum neurofilament, a biomarker for axonal damage, in the SYNERGY study as a complement to opicinumab zreatment effect in MS Ankur Sharma
EP1572 Multicenter sensory and motor evoked potentials: definition of improvement beyond measurement variability in single subjects Martin Hardmeier
EP1573 IgM MOG antibodies associated with cerebral lymphoma and CLIPPERS syndrome Klaus Jun. Berek
EP1575 Long-term prognostic value of anti myelin antibodies in multiple sclerosis Laura De Giglio
EP1576 Quality controls in biobank samples: effects of pre-analytical factors on blood samples used in gene expression studies Paola Valentino
EP1577 Differential effects of dimethyl fumarate on peripheral blood mononuclear cells of relapsing-remitting multiple sclerosis patients and prognostic implications Alicia Sánchez Sanz
EP1578 MicroRNAs and their use as biomarkers in clinically isolated syndrome and multiple sclerosis Jette Lautrup Frederiksen
EP1579 Circulating microRNAs as biomarkers in multiple sclerosis Julia Vistbakka
EP1580 Looking for prognostic factors in MS: the simultaneous absence of IgGOB and spinal cord lesions at diagnosis identifies a less aggressive disease course Marco Puthenparampil
EP1581 The link between epigenetic regulators, neurotrophins and treatment efficacy in patients with multiple sclerosis Fatih Söke
EP1582 Siponimod increases brain-derived neurotrophic factor (BDNF) levels in cortical neuronal cultures and naïve healthy mice Anna Schubart
EP1583 Explaining long-term depletion of memory B lymphocytes after cladribine treatment Benjamin Jacobs
EP1584 Alemtuzumab in highly active MS: effectiveness in real life and the need of immunological profiling Nicola De Rossi
EP1585 Switching inactive MS patients under BRACE therapies to teriflunomide due to injection-related problems Filipa Ladeira
EP1586 Comparison of fingolimod and teriflunomide on the basis of relapse, magnetic resonance imaging and cognition following the switch from injectables in patients with stable multiple sclerosis Serkan Ozakbas
EP1587 Long-term remission of tumefactive relapsing multiple sclerosis after alemtuzumab rescue treatment in an adolescent patient Pietro Annovazzi
EP1588 Cyclophosphamide in multiple sclerosis: a real-life study on 222 patients Pacôme Constant Dit Beaufils
EP1589 Patient initiation of fingolimod treatment in younger patients with multiple sclerosis in clinics and in the Gilenya@Home Program John Osborne
EP1590 Effects of MS treatments on the phenotypic and functional characteristics of B cells Thomas Guerrier
EP1591 Synthesis and preliminary testing of siRNA targeting the T Cell receptor β-chain - A proposed therapy for the treatment of autoimmunity Nicholas Magazine
EP1592 Characterization of myelin peptide-coupled red blood cells Muriel Hohmann
EP1593 Dissection of the distinct susceptibility of hematopoietic precursors and immune cells to cladribine Antonio Uccelli
EP1594 Multiple sclerosis relapse resolution with corticosteroid alternatives: a retrospective claims analysis of us health plan data Tzy-Chyi Yu
EP1595 Peginterferon beta-1a every 2 weeks demonstrated better clinical outcomes than glatiramer acetate once-daily in patients with RRMS: propensity score matching of phase 3 data from ADVANCE and CONFIRM Thomas F. Scott
EP1596 Ocrelizumab in an expanded cohort of primary progressive MS patients: safety outcomes and clinical/paraclinical follow-up Giovanni Novi
EP1597 Efficacy of teriflunomide in a progressive multiple sclerosis cohort in the CLIMB study James Stankiewicz
EP1598 Real-world data on alemtuzumab treatment of relapsing multiple sclerosis: a two-year prospective one center study Sofia Sandgren
EP1599 Effect of RAM589.555 on viability, proliferation and expression of brain derived neurotrophic factor of primary mouse microglia and astrocytes in vitro Rina Zilkha-Falb
EP1600 Evaluation of efficacy of glatiramer acetate treatment for multiple sclerosis in Japan Tomoko Okamoto
EP1601 Disease modifying treatments (DMTs) in Germany - changes in treatment patterns Alexander Stahmann
EP1602 Disease-modifying therapy of paediatric onset multiple sclerosis. A nationwide Danish cohort study Melinda Magyari
EP1603 Skin warts during fingolimod treatment in patients with multiple sclerosis Maya Zeineddine
EP1604 A new place for mitoxantrone in the treatment of multiple sclerosis Łukasz Rzepiński
EP1605 Teri-CARE study design and baseline characteristics of the full study population: assessing changes in quality of life in teriflunomide-treated patients Guillermo Izquierdo
EP1606 Teriflunomide reduces spontaneous lymphoproliferation of peripheral blood mononuclear cells from patients with human T-lymphotropic virus (HTLV)-1-associated myelopathy/tropical spastic paraparesis Yoshimi Akahata
EP1607 Anti-inflammatory responses by oral administration of iNKT cell ligand OCH in healthy human and multiple sclerosis: results of investigator-initiated, first-in-human phase 1 study Wakiro Sato
EP1608 Neuroblastoma cell line and lymphocytes talk for cladribine influenced apoptosis and inflammation pathways in multiple sclerosis (MS): an “in vitro” study Maddalena Ruggieri
EP1609 Dimethyl fumarate treatment differentially impairs frequency and function of activated, mature B cells Jan Traub
EP1610 Effect of dimethyl fumarate on the development of type-II innate immune cells and CNS-infiltration of M1 macrophages Suhayl Dhib Jalbut
EP1611 Peginterferon beta-1a safety and efficacy in real-life clinical setting: a prospective, multicenter follow-up study Rocco Totaro
EP1612 Analysis of therapeutic regimens and treatment switch patterns in specific clinical forms of multiple sclerosis using big data Marie Trad
EP1613 Pharmacokinetics and pharmacodynamics of PEGylated interferon beta-1a in patients with relapsing-remitting multiple sclerosis in the randomized double-blind placebo-controlled study Arina Zinkina-Orikhan
EP1614 Experience with Secukinumab in multiple sclerosis Virginia Meca-Lallana
EP1615 Immunomodulatory molecules on plasmacytoid dendritic cell is associated with decreased neurofilament light in the cerebrospinal fluid of patients with multiple sclerosis treated with natalizumab Leonilda Maria Barbosa Santos
EP1616 A retrospective observational study of rituximab in multiple sclerosis patients in Cyprus Eleni Leonidou
EP1617 The S1P5 receptor is not down-modulated in response to selective agonists Marc Bigaud
EP1618 Optimising Siponimod (BAF312) oral administration for long-term experimental studies in mice Philipp Albrecht
EP1619 Phase 2 AFFINITY trial evaluates opicinumab in a targeted population of patients with relapsing multiple sclerosis: rationale, design and baseline characteristics Bing Zhu
EP1620 Effect of MD1003 (high dose pharmaceutical grade biotin) on dexterity, cognitive, and quality of life measures in a cohort of patients with non-active progressive multiple sclerosis Cecile Donze
EP1621 Disability stabilization in multiple sclerosis under teriflunomide treatment Francesca Sangalli
EP1622 Treatment with dimethyl fumarate enhances cholinergic transmission in multiple sclerosis Carolina G Nicoletti
EP1623 Remyelination promoting therapies in multiple sclerosis animal models: a systematic review and meta-analysis Benjamin V. Ineichen
EP1624 A prospective study of disease modifying therapy and retinal atrophy in multiple sclerosis Anna Kabanovski
EP1625 Frequency and description of relapses in a cohort of progressive multiple sclerosis patients treated with high dose biotin Bruno Brochet
EP1626 Long-term effect of natalizumab in a French cohort of patients with RRMS: TYSTEN cohort Kevin Bigaut
EP1627 Integration of ocrelizumab safety data from the German study CONFIDENCE into the global post-marketing safety studies MANUSCRIPT and VERISMO Tjalf Ziemssen
EP1628 A comparison of efficacy of subcutaneous interferon beta-1a 44 µg, dimethyl fumarate and fingolimod in the real-life clinical practise, a multicenter observational study Zbyšek Pavelek
EP1629 The BELTRIMS registry: real-world safety and efficacy of DMTs in Belgium Barbara Willekens
EP1630 Prospective real world observational multi-center study in patients with relapsing-remitting multiple sclerosis treated with dimethyl fumarate in Campania, Italy Roberta Lanzillo
EP1631 Clinical characteristics of relapsing-remitting multiple sclerosis patients with persistent lymphopenia with dimethyl fumarate and comparison with no lymphopenic patients Rocío López Ruiz
EP1632 The potential influence of long term individualized patient coaching to optimize therapy management and address challenges in an individualized patient support program Mathias Mäurer
EP1633 A Swedish nationwide pharmaco-epidemiological study of the long-term safety and effectiveness of teriflunomid (IMSE 4) Selin Safer Demirbüker
EP1634 Early stages of disability in patients with multiple sclerosis by physician and patient-reported outcomes: a two-year study Maria Wunderlich
EP1635 Autoimmune alopecia totalis; a complication of alemtuzumab therapy in multiple sclerosis Wilson Ka Wai Fung
EP1636 A milestone in multiple sclerosis treatment: what changed in the landscape of the multiple sclerosis treatment with oral medications Serkan Ozakbas
EP1637 Skin autoimmune problems following alemtuzumab treatment in multiple sclerosis Maria Ruiz de Arcos
EP1638 Real life effectiveness and safety of teriflunomide in relapsing-remiting multiple sclerosis (RRMS): a MS reference center-based observational study with two years follow-up Jose Eustasio Meca Lallana
EP1639 Real-world effectiveness and safety of pegylated interferon beta-1a in patients with multiple sclerosis: a multicentre retrospective study in Central Italy Shalom Haggiag
EP1640 Real-world longitudinal data of peginterferon beta-1a from a Swedish national post-marketing surveillance study (IMSE 6) - efficacy and safety profile Stina Kågström
EP1641 The Multiple Sclerosis Data Alliance: better data for better decision making, a multi-stakeholder approach Liesbet M. Peeters
EP1642 Real world effectiveness of fingolimod in patients with relapsing remitting multiple sclerosis and non-response to previous treatment: a prospective analysis in Buenos Aires, Argentina Juan Rojas
EP1643 Efficacy of alemtuzumab treatment in active RRMS - a real-life study Ofir zmira
EP1644 Guillain-Barré syndrome after treatment with alemtuzumab in a patient with multiple sclerosis Claudia Balducci
EP1645 Spanish registry of multiple sclerosis patients on glatiramer acetate 40 mg/ml treatment: real-world results and initial results of first year follow-up Oscar Fernandez
EP1646 Real World Evidence (RWE) on impact of age on long-term persistence to disease modifying therapies (DMTs) in relapsing-remitting multiple sclerosis (RRMS) in Australia Tim Spelman
EP1647 Very long term use of natalizumab is possible but carries a high burden Elisa Matias Vieira Melo
EP1648 Patients switching to fingolimod in daily clinical routine: 2 year interim results from the non-interventional study PANGAEA 2.0 Ulf Schulze-Topphoff
EP1649 Clinical protocol for the prevention of rebound phenomenon after natalizumab cessation in multiple sclerosis. A multiple sclerosis reference center experience Luna Fuentes Rumí
EP1650 Evolving predictors to medication adherence in patients with MS - a prospective analysis with multiple indicators Anat Wolkovich
EP1651 17 - year adherence to interferon beta-1b treatment in patients with multiple sclerosis Carmen Adella Sirbu
EP1652 Comparative efficacy of natalizumab and fingolimod in multiples sclerosis in a Tunisian population Ahmed Ghariani
EP1653 Delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis - findings from a real-world setting in Russian Federation Maria Davydovskaya
EP1654 Comparison of use oral and injection disease-modifying therapies in persons with multiple sclerosis Taha Aslan
EP1655 Serious adverse events related to Rituximab in multiple sclerosis and neuromyelitis optica spectrum disorder patients Lana Zhovtis Ryerson
EP1656 Quality of life improves with alemtuzumab over 6 years even in patients with relapsing-remitting multiple sclerosis who developed thyroid adverse events Tjalf Ziemssen
EP1657 Daclizumab: side effects and efficacy in a real world setting Sandra Raunegger
EP1658 Tuberculosis screening in the setting of multiple sclerosis disease modifying therapies Laura Baldassari
EP1659 Patients' perception about risk and benefit in disease modifying therapies: an Italian multicentric survey Mariavittoria Turrini
EP1660 Pharmacy-led prescribing of natalizumab in MS patients improves the quality of monitoring and overall safety Rachel Dorsey-Campbell
EP1661 Effectiveness of reduced fingolimod dosage in relapsing remitting multiple sclerosis - a Portuguese cohort Joana Ramos Lopes
EP1662 Disease-modifying treatment and infectious risk in patients with multiple sclerosis - the experience of a Portuguese tertiary care hospital Daniela Ferro
EP1663 Tuberculosis screening in patients with multiple sclerosis who are candidates for natalizumab and fingolimod in a Portuguese tertiary centre Sara Duarte
EP1664 Genomic profiling and in vivo rat toxicity characterization of Copaxone and the Synthon European follow-on glatiramer acetate product Pippa Loupe
EP1665 Risk of pulmonary embolism in patients with multiple sclerosis on dimethyl fumarate Gracy Juba
EP1666 Recurrent autoimmune uveitis after alemtuzumab treatment for multiple sclerosis Erika Portera
EP1667 Prevalence of therapeutic inertia in multiple sclerosis care in Argentina: results from EDUCAR MS Argentina Fernando Caceres
EP1668 Fingolimod cessation and multiple sclerosis rebound syndrome: a case report and literature review Giordani dos Passos
EP1669 "We'll test your blood for an infection that might kill you" - a qualitative study describing how risks of disease modifying treatment are communicated to people with relapsing multiple sclerosis Ana Manzano
EP1670 Early onset autoimmune manifestations after alemtuzumab treatment for multiple sclerosis: a single-center cohort study Aglaia Vakrakou
EP1671 Hepatitis B reactivation in a patient with primary progressive multiple sclerosis under ocrelizumab treatment Marco Iannetta
EP1672 A case of immune-mediated encephalitis related to daclizumab therapy Stefan Blum
EP1673 Brain atrophy estimation from incomplete clinically-acquired MRI scans - a validation of the MS ´Frankenstein´ approach Margareta Clarke
EP1674 Using label-free NAD(P)H-FLIM to monitor effect of teriflunomide on NOX enzyme activation in CNS cells Helena Radbruch
EP1675 Deep learning for cell-specific high-throughput quantification of oligodendrocyte ensheathment Jack Antel
EP1676 White matter diffusion and myelin integrity improvement after 6 months of fingolimod treatment in relapsing-remitting multiple sclerosis Svetlana Bezukladova
EP1677 Evaluation of dimethylfumarate in treatment of focal DTH and MOG EAE using TSPO-PET imaging Susanne K Vainio
EP1678 Comparative analysis of natalizumab versus fingolimod by including cortical lesions into NEDA-3 concept Marco Puthenparampil
EP1679 PROMiS (a prospective, non-interventional study in US patients with relapsing-remitting multiple sclerosis treated with alemtuzumab in routine clinical practice): interim results on treatment history and satisfaction with alemtuzumab Bhupendra O Khatri
EP1680 Elevated neurofilament light chain levels in progressive multiple sclerosis effectively reduced by cladribine treatment Ozlem Yildiz
EP1681 Tolerability and persistence in therapy with PEGylated-IFN: results from a multicentric observational study in northern Italy Pietro Annovazzi
EP1682 Comparative efficacies of dimethyl fumarate and fingolimod in quantitative radiographic disease measures using clinical MRI Jenny Feng
EP1683 Favorable response to disease modifying treatments in Chinese patients with relapsing multiple sclerosis - results from a prospective registry in Hong Kong Chung Kwan Au
EP1684 Italian botulinum toxin network study on the management of spasticity in multiple sclerosis Marcello Moccia
EP1685 “I'm in a very good frame of mind”: the experience of standing frame use in people with progressive multiple sclerosis Louise Jarrett
EP1686 Biofeedback based home balance training can improve balance but not gait in people with multiple sclerosis Klara Novotna
EP1687 Does cognitive training improve attention/working memory in persons with MS? A pilot study using the Cogmed Working Memory Training program Sarah Anne Morrow
EP1688 Implementing cognitive rehabilitation for people with multiple sclerosis: translating research into clinical practice Jacqueline R Mhizha-Murira
EP1689 Medical and recreational cannabis use in patients with multiple sclerosis in Denmark Stefan Gustavsen
EP1690 A prospective observational registry of repository corticotropin injection for the treatment of multiple sclerosis relapse: baseline characteristics and updated interim results Bryan Due, PhD
EP1691 Work out training, coordination training and an active control condition improved subjective sleep, fatigue and symptoms of depression and anxiety among female patients with multiple sclerosis (MS) Dena Sadeghi Bahmani
EP1692 Intrathecal phenol is a forgotten treatment option for severe lower limb spasticity in advanced multiple sclerosis Sara Simeoni
EP1693 Evaluation of the cognitive benefits of intrathecal baclofen pump implantation in subjects with intractable MS related spasticity Rachel Farrell
EP1694 THC/CBD oromucosal spray in patients with multiple sclerosis bladder dysfunction: a pilot prospective study Valentina Torri Clerici
EP1696 A survey of cannabis-based product use in multiple sclerosis patients at the University of British Columbia Hospital Alice Jane Schabas
EP1697 Acute aphasia responsive to tissue plasminogen activator in an 8-week pregnant multiple sclerosis patient after discontinuation of fingolimod Brian Barry
EP1698 Efficacy and discontinuation of nabiximols in patients with multiple sclerosis: a real-life study Valeria Bergamaschi
EP1699 The impact of treating obstructive sleep apnoea syndrome on cognitive function in people with multiple sclerosis Nuala McNicholas
EP1700 The effect of pilates exercise on balance, postural instability, functional capacity and quality of life in multiple sclerosis patients Nur Yüceyar
EP1701 Intrathecal baclofen should be considered in ambulatory people with multiple sclerosis related spasticity: an observational study Yezen Sammaraiee
EP1702 Substantial improvement of walking after fampridine introduction indicates improvement of meaningful and self-chosen activities of daily living in patients with multiple sclerosis Gregor Brecl Jakob
EP1703 Virtual reality training to improve upper limb motor function in multiple sclerosis: a feasibility study protocol Alon Kalron
EP1704 The influence of multiple sclerosis therapies on headache Yesim Beckmann
EP1705 Physicians' gender differences in risk perception and therapeutic inertia in multiple sclerosis care Gustavo Saposnik
EP1706 Early experience with ocrelizumab: patient characteristics from a large insurance claims database Natalie J Engmann
EP1707 Closing the gaps for MS treatment adherence at low middle income countries. Egypt case Abdalla Abotaleb
EP1708 Locked-in-syndrome in a patient with tumefactive multiple sclerosis Frank Thömke
EP1709 Self-esteem partially mediates the relationship between quality of life and depression in multiple sclerosis patients Egemen İdiman
EP1710 Online medical education improves knowledge of immune mechanisms in the treatment of MS among neurologists Thomas Finnegan
EP1711 A global nurse-focused Delphi approach to management of gastrointestinal tolerability of dimethyl fumarate Trudy L. Campbell
EP1712 Is the primary use of generic (non-propietary) disease modifying therapies (DMTs) associated with therapeutic inertia in multiple sclerosis care? Fernando Caceres
EP1713 Pilates exercise has positive effect on balance but not on gait performance in people with mild multiple sclerosis Klara Novotna
EP1714 1 year-healthy outcomes in RRMS patients treated with teriflunomied and dimethyl fumarate Inés González-Suárez
EP1715 TeleSEP: development of platform to regional tele-expertise in multiple sclerosis Nathalie Derache
EP1716 Is itIt's possible to continue a really effective therapy in a patient with a severe hypersensitivity drug reaction? The importance of desensitization procedures in the monoclonal antibodies era Lucia Moiola
EP1717 High-dose biotin in progressive multiple sclerosis : a prospective study of 86 patients in routine clinical practice Laura Couloume
EP1718 Treatment of spasticity in patients with multiple sclerosis by using method of electrical stimulation according to Jantsch - a pilot study Martina Kovari
EP1719 MS in the 21st Century mapping study identifying the global educational offerings for multiple sclerosis patients Sven Schippling
EP1720 Wind of change: an Italian initiative to promote water sports in people with multiple sclerosis Andrea Tacchino
EP1721 Is placebo effect getting bigger in randomized controlled trials of multiple sclerosis? Murat Kurtuncu
EP1722 Making science digestible: the development of educational activities for children with a parent with MS, and the need to better engage families Alison Thomson
EP1723 Young MS in Italy: attitude towards present and expectations for the future Mario Alberto Battaglia
EP1724 Attendance to ECTRIMS: does it impact on therapeutic decisions in multiple sclerosis care? Gustavo Saposnik
EP1725 Fulminant multifocal relapse in a fingolimod-treated patient Agustina M. Lascano
EP1726 Demographic and clinical characteristics of patients treated with ocrelizumab in the United States Natalie J Engmann
EP1727 Effect of pregnancy and exclusive breastfeeding on the rate of relapses and degree of disability in two years after pregnancy in patients with multiple sclerosis Mehran Ghaffari
EP1728 Fuelling patient engagement in health: perceptions and utilisation of patient self-monitoring Hannah Brown
EP1729 Idiopathic thrombocytopenic purpura (ITP) during Fingolimod treatment in relapsing remitting multiple sclerosis Negar Molazadeh
EP1730 Digging up a new approach in the management of multiple sclerosis: Helminth therapy from the patients' perspective Megan C Kirkland
EP1731 A comparison of the effects of yoga and clinical pilates exercise on mobility, respiratory muscle strength and cognition in persons with multiple sclerosis Zuhal Abasiyanik
EP1732 EDSS score, age, disease type and inaccessibility impact on oral health and prosthodontic rehabilitation in multiple sclerosis patients of a Hellenic cohort Maria Anagnostouli
EP1733 The main factors that influence the family life of patients with multiple sclerosis Ionela A. Ionescu
EP1734 Hepatitis B post-vaccination immunogenicity in multiple sclerosis patients undergoing immunomodulators Silvia Presas-Rodriguez
EP1735 Methylprednisolone concentration in milk and serum during and shortly after IV pulse therapy in patients with MS Cavit Boz
EP1736 Effects of methyl prednisolone on the proliferation and maturation of oligodentrocytes. In vitro study Paloma Montero-Escribano
EP1737 Real-world effectiveness of TYSABRI® (natalizumab) treatment in patients with relapsing remitting multiple sclerosis in Argentina and Chile Célica Ysrraelit
EP1738 Multiple sclerosis prognosis - our experience in Colentina Clinical Hospital Oana Rujan